



201 Technology Drive • Irvine • California • 92618
Telephone: (949) 450-5400
Facsimile: (949) 450-5300
Email: IR@endocare.com
Website: www.endocare.com

FOR RELEASE on August 22, 2008 at 6:00 am (EDT)

Investor Contact:

Matt Clawson
Allen & Caron, Inc.
(949) 474-4300
matt@allencaron.com
www.allencaron.com

Media Contact:

Len Hall
Allen & Caron, Inc.
(949) 474-4300
len@allencaron.com
www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO
Michael R. Rodriguez, CFO
Endocare, Inc.
(949) 450-5400
www.endocare.com

**ENDOCARE AND FORMER CFO AGREE TO TERMINATE
INDEMNIFICATION AGREEMENT**

IRVINE, Calif. (August 22, 2008) . . . Endocare, Inc. (NASDAQ:ENDO) announced today that it has entered into an agreement with its former CFO, John V. Cracchiolo, pursuant to which Mr. Cracchiolo's indemnification agreement was terminated in exchange for Endocare's waiver of certain severance and legal fee reimbursement rights. For September 2008 through December 2008, the Company had budgeted over \$875,000 for Mr. Cracchiolo's legal costs. As a result of this new agreement, the Company is no longer obligated to pay any future legal costs for Mr. Cracchiolo.

Please see the related Form 8-K filed by Endocare with the Securities and Exchange Commission this morning.

About Endocare

Endocare, Inc.—www.endocare.com— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###